164 related articles for article (PubMed ID: 30416780)
21. Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma.
Kato H; Arao T; Matsumoto K; Fujita Y; Kimura H; Hayashi H; Nishiki K; Iwama M; Shiraishi O; Yasuda A; Shinkai M; Imano M; Imamoto H; Yasuda T; Okuno K; Shiozaki H; Nishio K
Int J Oncol; 2013 Apr; 42(4):1151-8. PubMed ID: 23426935
[TBL] [Abstract][Full Text] [Related]
22. Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma.
Wheeler S; Siwak DR; Chai R; LaValle C; Seethala RR; Wang L; Cieply K; Sherer C; Joy C; Mills GB; Argiris A; Siegfried JM; Grandis JR; Egloff AM
Clin Cancer Res; 2012 Apr; 18(8):2278-89. PubMed ID: 22351687
[TBL] [Abstract][Full Text] [Related]
23. Predictive value of EGFR overexpression and gene amplification on icotinib efficacy in patients with advanced esophageal squamous cell carcinoma.
Wang X; Niu H; Fan Q; Lu P; Ma C; Liu W; Liu Y; Li W; Hu S; Ling Y; Guo L; Ying J; Huang J
Oncotarget; 2016 Apr; 7(17):24744-51. PubMed ID: 27013591
[TBL] [Abstract][Full Text] [Related]
24. Cetuximab inhibits cisplatin-induced activation of EGFR signaling in esophageal squamous cell carcinoma.
Kwon J; Yoon HJ; Kim JH; Lee TS; Song IH; Lee HW; Kang MC; Park JH
Oncol Rep; 2014 Sep; 32(3):1188-92. PubMed ID: 24993015
[TBL] [Abstract][Full Text] [Related]
25. Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
Stewart EL; Mascaux C; Pham NA; Sakashita S; Sykes J; Kim L; Yanagawa N; Allo G; Ishizawa K; Wang D; Zhu CQ; Li M; Ng C; Liu N; Pintilie M; Martin P; John T; Jurisica I; Leighl NB; Neel BG; Waddell TK; Shepherd FA; Liu G; Tsao MS
J Clin Oncol; 2015 Aug; 33(22):2472-80. PubMed ID: 26124487
[TBL] [Abstract][Full Text] [Related]
26. Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models.
Hou W; Qin X; Zhu X; Fei M; Liu P; Liu L; Moon H; Zhang P; Greshock J; Bachman KE; Ye BC; Wang H; Zang CY
Oncol Rep; 2013 Aug; 30(2):707-14. PubMed ID: 23708506
[TBL] [Abstract][Full Text] [Related]
27. Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models.
Wu X; Zhang J; Zhen R; Lv J; Zheng L; Su X; Zhu G; Gavine PR; Xu S; Lu S; Hou J; Liu Y; Xu C; Tan Y; Xie L; Yin X; He D; Ji Q; Hou Y; Ge D
J Transl Med; 2012 Aug; 10():180. PubMed ID: 22935382
[TBL] [Abstract][Full Text] [Related]
28. Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature.
Guo S; Chen D; Huang X; Cai J; Wery JP; Li QX
Oncotarget; 2016 Aug; 7(31):50575-50581. PubMed ID: 27409671
[TBL] [Abstract][Full Text] [Related]
29. Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas.
Gonzaga IM; Soares-Lima SC; de Santos PT; Blanco TC; de Reis BS; Quintella DC; de Oliveira IM; de Faria PA; Kruel CD; Andreollo NA; de Simão TA; Pinto LF
BMC Cancer; 2012 Dec; 12():569. PubMed ID: 23207070
[TBL] [Abstract][Full Text] [Related]
30. Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice.
Gong JH; Liu XJ; Li Y; Zhen YS
Cancer Chemother Pharmacol; 2012 May; 69(5):1323-32. PubMed ID: 22311160
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic Efficacy of GC1118, a Novel Anti-EGFR Antibody, against Glioblastoma with High EGFR Amplification in Patient-Derived Xenografts.
Lee K; Koo H; Kim Y; Kim D; Son E; Yang H; Lim Y; Hur M; Lee HW; Choi SW; Nam DH
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33142709
[TBL] [Abstract][Full Text] [Related]
32. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
Bertotti A; Migliardi G; Galimi F; Sassi F; Torti D; Isella C; Corà D; Di Nicolantonio F; Buscarino M; Petti C; Ribero D; Russolillo N; Muratore A; Massucco P; Pisacane A; Molinaro L; Valtorta E; Sartore-Bianchi A; Risio M; Capussotti L; Gambacorta M; Siena S; Medico E; Sapino A; Marsoni S; Comoglio PM; Bardelli A; Trusolino L
Cancer Discov; 2011 Nov; 1(6):508-23. PubMed ID: 22586653
[TBL] [Abstract][Full Text] [Related]
33. Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter Phase 2 Study.
Huang J; Fan Q; Lu P; Ying J; Ma C; Liu W; Liu Y; Tan F; Sun Y
J Thorac Oncol; 2016 Jun; 11(6):910-7. PubMed ID: 26980473
[TBL] [Abstract][Full Text] [Related]
34. Basal subtype is predictive for response to cetuximab treatment in patient-derived xenografts of squamous cell head and neck cancer.
Klinghammer K; Otto R; Raguse JD; Albers AE; Tinhofer I; Fichtner I; Leser U; Keilholz U; Hoffmann J
Int J Cancer; 2017 Sep; 141(6):1215-1221. PubMed ID: 28560858
[TBL] [Abstract][Full Text] [Related]
35. Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine.
Rivera M; Fichtner I; Wulf-Goldenberg A; Sers C; Merk J; Patone G; Alp KM; Kanashova T; Mertins P; Hoffmann J; Stein U; Walther W
Neoplasia; 2021 Jan; 23(1):21-35. PubMed ID: 33212364
[TBL] [Abstract][Full Text] [Related]
36. The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.
Jia J; Cui Y; Lu M; Wang X; Li J; Li J; Li Y; Zhang X; Gao J; Zhou J; Lu Z; Gong J; Yu J; Sun Z; Liu C; Shen L; Zhang X
Clin Transl Oncol; 2016 Jun; 18(6):592-8. PubMed ID: 26459251
[TBL] [Abstract][Full Text] [Related]
37. 111In-cetuximab-F(ab')2 SPECT imaging for quantification of accessible epidermal growth factor receptors (EGFR) in HNSCC xenografts.
van Dijk LK; Hoeben BA; Stegeman H; Kaanders JH; Franssen GM; Boerman OC; Bussink J
Radiother Oncol; 2013 Sep; 108(3):484-8. PubMed ID: 23932156
[TBL] [Abstract][Full Text] [Related]
38. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.
Licitra L; Mesia R; Rivera F; Remenár É; Hitt R; Erfán J; Rottey S; Kawecki A; Zabolotnyy D; Benasso M; Störkel S; Senger S; Stroh C; Vermorken JB
Ann Oncol; 2011 May; 22(5):1078-1087. PubMed ID: 21048039
[TBL] [Abstract][Full Text] [Related]
40. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus.
Hanawa M; Suzuki S; Dobashi Y; Yamane T; Kono K; Enomoto N; Ooi A
Int J Cancer; 2006 Mar; 118(5):1173-80. PubMed ID: 16161046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
